Description

COMPOSITION: Cefuroxime Axetil 500 mg + Clavulanic Acid 125 mg

Cefuroxime Axetil (Cephalosporin antibiotics)

• Cefuroxime-axetil is the first oral broad-spectrum cephalosporin to be naturally stable in the presence of bêta-lactamases.

 

• For the treatment of upper respiratory tract infection, clinical success was achieved for 94.3% of the patients treated with cefuroxime-axetil versus 90.4% for cefadroxil. 

• Cefuroxime is metabolically stable, and relatively free of serious side effects.  

Clavulanic acid (Beta-lactamase inhibitors)

• Clavulanic acid is a potent inhibitor of many β-lactamases, including those found in Escherichia coli, and Staphylococcus aureus, the inhibition being of a progressive type. Antimicrob Agents Chemother. 

• Clavulanic acid acts synergistically with cephalosporins against β-lactamase-producing enteric bacteria to inhibit sensitive β-lactamases, thus allowing the companion β-lactam to kill the bacteria.

• Effectively extends the spectrum to include many bacteria normally resistant to cefuroxime and other β-lactam antibiotics.

COMBINATION

• The combination of Cefuroxime axetil and clavulanic acid (Beta-Lactamaes inhibitor) provides a solution for the treatment of bacterial infections caused by beta lactam resistant pathogens. 

• They are prescription antibiotic medication. It is used to treat a variety of infections. 

• The combination of cefuroxime axetil and clavulanic acid (beta-lactamases inhibitor) provides a solution for the treatment of bacterial infections caused by beta lactam-resistant pathogens. 

• Cefuroxime axetil and clavulanic acid can be used as a second-line therapy where cefuroxime axetil alone is not able to show its bactericidal activity. 

• Clavulanic acid acts as a beta-lactamase inhibitor thus making cefuroxime axetil effective against resistant bacteria.